Yozma Group Korea-Backed Alpha Tau Achieves 100% Response Rate in U.S. Brain Tumor Trial, Joins Tel Aviv Benchmark Indices

KO YONG-CHUL Reporter

korocamia@naver.com | 2026-11-20 05:35:34

Interim results from U.S. recurrent glioblastoma trial show all 8 treated patients survived and all 6 evaluable patients exhibited tumor response

Interim results from U.S. recurrent glioblastoma trial show all 8 treated patients survived and all 6 evaluable patients exhibited tumor response
Added to Tel Aviv Stock Exchange’s TA-90 and TA-125 indices, becoming one of only three biomed firms in the TA-125
Yozma Group Korea spearheaded Nasdaq listing investment; pledges to continue serving as a "Korea-Israel bio bridge"

SEOUL, South Korea — Yozma Group Korea announced on November 19 that its portfolio company, Israeli oncology therapeutics firm Alpha Tau Medical (NASDAQ, TASE: DRTS, hereinafter "Alpha Tau"), reported positive interim results from a U.S. clinical trial targeting recurrent glioblastoma. Earlier this month, Alpha Tau was also added to the benchmark indices of the Tel Aviv Stock Exchange (TASE). Having participated as an investor since Alpha Tau’s Nasdaq listing phase, Yozma Group Korea has continuously bridged investments and partnerships with Korean companies.

Positive Interim Results in U.S. Recurrent Glioblastoma Trial On November 15 (local time), Alpha Tau unveiled interim clinical results for its alpha-radiation cancer therapy device, "Alpha DaRT," for recurrent glioblastoma at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting. All eight patients treated without craniotomy remain alive, and all six patients who completed response evaluations experienced tumor shrinkage, achieving a 100% objective response rate (ORR). Notably, five of these six patients achieved a complete response (CR), with tumors completely disappearing from the treated areas. Given that these are interim results based on a small cohort, the company plans to continue long-term follow-ups and expand patient enrollment up to 20 subjects.

Developed by researchers at Tel Aviv University in Israel, Alpha DaRT is a technology that destroys cancer cells using alpha radiation by inserting radioactive sources directly into the tumor. While the therapy received marketing approval in Japan in February of this year for the treatment of head and neck cancer, it has not yet been approved for glioblastoma.

Inclusion in Tel Aviv Stock Exchange Benchmark Indices Prior to the clinical announcement, Alpha Tau was added to the Tel Aviv Stock Exchange’s TA-90 and TA-125 indices on November 5. This milestone came just three months after the company dual-listed on TASE in August by registering all of its issued shares alongside its Nasdaq listing. The TA-125 tracks the 125 leading companies on the Israeli stock market, and Alpha Tau is now one of only three biomedical companies included in the index. Following this inclusion, index-tracking funds are expected to add Alpha Tau shares to their portfolios.

Uzi Sofer, CEO of Alpha Tau, expressed expectations that joining the indices just months after dual-listing will boost recognition among Israeli institutional investors and expand the local shareholder base and trading volume. He added that the ability to trade in either U.S. dollars or Israeli shekels—and during both U.S. and Israeli market hours—enhances liquidity, offering significant benefits to shareholders worldwide.

From Nasdaq Listing Investment to Domestic Partnerships in Korea Alpha Tau initially announced a merger with special purpose acquisition company (SPAC) Healthcare Capital Corp. in July 2021, valuing the post-merger entity at approximately $1 billion and structuring the deal to raise up to $367 million upon listing. Yozma Investment, an affiliate of Yozma Group Korea, participated as an anchor investor in the $92 million Private Investment in Public Equity (PIPE) priced at $10 per share, alongside Israeli crowdfunding platform OurCrowd and pharmaceutical firm Medison. Alpha Tau subsequently debuted on the Nasdaq in March 2022.

Beyond capital investment, Yozma Group Korea actively fostered ties between Alpha Tau and Korean enterprises. During a visit to South Korea in August 2022 to discuss collaborations with local hospitals, universities, and corporations, Alpha Tau signed a Memorandum of Understanding (MOU) for R&D, manufacturing, and production cooperation with strategic investor Estech Pharma (now Polaris AI Pharma). Yozma Group Korea has continued to facilitate local exchanges and lay the groundwork for strategic partnerships. Building on these efforts, Alpha Tau and Samsung Medical Center signed an MOU in October 2026 to discuss launching domestic clinical trials of Alpha DaRT for pancreatic cancer patients.

"Alpha Tau is a prime example of Korean capital and corporations participating early in innovative Israeli technology and growing together in the global capital market," said Won-jae Lee, CEO of Yozma Group Korea. "Yozma Group Korea will continue to serve as a bridge connecting promising Israeli technologies with Korean businesses and investors so that bilateral bio cooperation leads to tangible outcomes."

Meanwhile, Yozma Group Korea is the Korean subsidiary of the Yozma Group, which originated in 1993 from the Yozma Fund—a joint public-private venture capital initiative by the Israeli government. Since its establishment in 2015, Yozma Group Korea has formed 42 venture and new technology investment funds, accumulating 365 billion KRW in assets under management (AUM). It has invested in over 60 companies across the bio, deep-tech, and digital sectors, successfully leading two of its portfolio companies to Nasdaq IPOs.

[ⓒ Global Economic Times. 무단전재-재배포 금지]

WEEKLY HOT